StockNews.AI

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

StockNews.AI • 5 hours

AZAVEN
High Materiality8/10

Information

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'...

Original source

AI Summary

SELLAS Life Sciences has partnered with IMPACT-AML to expand SLS009 clinical trials into Europe, focusing on AML treatment. The collaboration is expected to enhance patient enrollment and capital efficiency, with first U.S. enrollments starting in Q1 2026 and European sites in Q2 2026, potentially boosting SLS's market position and valuation.

Sentiment Rationale

The partnership provides external validation and a pathway for enhanced clinical trial efficiency, potentially raising investor confidence. Historically, similar collaborations in biotech have led to stock price increases based on improved market access and operational capabilities.

Trading Thesis

Buy SLS on news of international clinical expansion, targeting a short-term gain around Q1 2026.

Market-Moving

  • Partnership with IMPACT-AML boosts credibility of SLS009 in AML therapies.
  • Anticipated enrollment numbers could signal strong investor interest.
  • Successful trials may lead to expedited market entry for SLS009.
  • Positive results could significantly increase SLS stock valuation.

Key Facts

  • SELLAS partners with IMPACT-AML for SLS009 clinical study in Europe.
  • SLS009 to evaluate AML treatment with AZA/VEN starting Q1 2026.
  • First U.S. patient enrollment planned for Q1 2026, Europe Q2 2026.
  • The collaboration enhances patient access and clinical efficiency in AML.
  • SLS009 shows promise in treating high-risk AML patients.

Companies Mentioned

  • SELLAS Life Sciences Group, Inc. (SLS): Focus on AML therapy may drive stock interest.
  • Azacitidine (AZA): Combining with SLS009 may enhance efficacy in the trial.
  • Venetoclax (VEN): Part of the new AML treatment regimen including SLS009.

Corporate Developments

This news fits into 'Corporate Developments' as it involves a strategic partnership aimed at clinical expansion, which may significantly affect SELLAS's market position and investor confidence in its lead product candidate.

SELLAS Life Sciences Expands SLS009 Clinical Program into Europe through IMPACT-AML Agreement

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a clinical biopharmaceutical company focused on innovative cancer therapies, has announced a strategic agreement with IMPACT-AML to broaden its SLS009 clinical program into frontline acute myeloid leukemia (AML) treatment in Europe.

Details of the Agreement

The collaboration with IMPACT-AML, a prominent European initiative aimed at accelerating innovative AML treatments, will facilitate the clinical evaluation of SLS009. This highly selective CDK9 inhibitor will be assessed across multiple clinical sites in Europe, enhancing patient enrollment capabilities.

IMPACT-AML integrates a diverse clinical network, including major research institutions such as IRST, the University of Bologna, and IIS LA FE, as well as various European AML collaborative groups and university hospitals. This strategic partnership will effectively capitalize on existing infrastructures to improve patient access to SLS009 in a cost-efficient manner.

Clinical Trial Plans and Schedule

The SLS009 clinical trial will enroll approximately 40 patients in Europe to evaluate its efficacy in combination with azacitidine and venetoclax (AZA/VEN) for patients with newly diagnosed AML. The U.S. enrollment is set to commence in Q1 2026, followed by European recruitment in Q2 2026, pending regulatory approvals and readiness of clinical sites.

  • Commencement of U.S. enrollment: Q1 2026
  • Commencement of European enrollment: Q2 2026
  • Number of patients enrolled: Approximately 40

Strategic Significance of the Collaboration

“This is a highly meaningful milestone for SELLAS and for the SLS009 program,” stated Dr. Angelos Stergiou, CEO of SELLAS. He emphasized that access to the IMPACT-AML framework symbolizes external validation and reflects the increasing recognition of SLS009’s potential in meeting critical unmet medical needs in AML.

This partnership is expected to enhance the efficiency of SELLAS’ clinical program. By leveraging established infrastructures, the company aims to improve capital efficiency while supporting broader patient enrollment.

Forward-Looking Statements and Company Overview

SELLAS Life Sciences Group, Inc. is dedicated to developing novel therapies for various cancer indications. Their leading product, SLS009 (tambiciclib), aims to be a differentiated small molecule CDK9 inhibitor with enhanced potency and reduced toxicity compared to existing options. Preliminary data indicates a promising response in AML patients with challenging prognostic factors, including those with the ASXL1 mutation.

For more details on SELLAS and its ongoing clinical programs, please visit www.sellaslifesciences.com.

Investor Contact

For media inquiries, please contact:

John Fraunces
Managing Director
LifeSci Advisors, LLC
Email: jfraunces@lifesciadvisors.com

Related News